|
Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus Clinical Trials Information presented on Clinical Trials Search is not intended to be a substitute for qualified health advice, trips or treatment by using a genuine doctor. We aren't doctors. Always consult your mD on Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus Clinical research trials and Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus health trials take place in a lot of of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / projects is to answer specific human medical questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, like Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus. Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus Clinical Trials and other clinical trials allow for volunteers to have health treatment alternatives before they are available to the general public. Many times the test subjects obtain treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus clinical trial. Subjects oftentimes recieve the most effective healthcare possible for their Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus condition. Hazards are a reality, however, and could include additional or frequent doctor visits, healthcare dangers (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus  Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus
Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus
For Condition: Diabetes Insipidus, Nephrogenic
Status: Completed
Sponsor(s): National Center for Research Resources (NCRR) , Northwestern University
Synopsis: OBJECTIVES: I. Determine the relationship between genotype variations and clinical phenotype in patients with congenital nephrogenic diabetes insipidus.
Details: PROTOCOL OUTLINE: A detailed family history is obtained from all participants. Whenever possible, standard growth curves of affected children are obtained. Participants then undergo clinical studies of antidiuretic function. A standard fluid deprivation-vasopressin challenge is performed with timed measurements of osmolality, electrolytes, creatinine, and vasopressin. The next day, blood pressure, plasma cyclic AMP, GMP, von Willebrand Factor, Factor VIII, and urine osmolality are measured during a water load desamino-D-arginine vasopressin (dDAVP) infusion test. Participants with a confirmed diagnosis of congenital diabetes insipidus are then treated with chlorothiazide. Daily urine volume and osmolality are determined before and after therapy. Sodium and fluid are not restricted. For each family, the entire vasopressin V2 gene of at least 1 affected male, and where possible at least 1 obligate carrier and 1 unaffected brother of a patient is sequenced. In addition, a detailed Xq28 haplotype analysis is done to identify the origin of de novo mutations. If no mutation is found and the disorder is not transmitted in an X-linked mode, both alleles of the gene that codes for aquaporin-II are also sequenced. DNA is collected by mail from as many kindred as possible who do not participate in the clinical studies.
Eligibility:
Study Type: Observational, Screening
Minimum Age/Maximum Age: 6 Months/70 Years
Genders: Both
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: - Known or suspected congenital nephrogenic diabetes insipidus - Clinically and genetically unaffected relatives entered as controls --Patient Characteristics-- - Age: 6 months to 70 years
Total Enrollment:
Location and Contact Information:
Overall Study Official:
GaryRobertson, Study Chair, Northwestern University
Additional Information:
Study ID Numbers: 199/11929; NU-513
Study Start Date: September 1995
Record last reviewed: December 1999
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00004360
Other Diabetes Insipidus, Nephrogenic Studies:
1. Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus
Related Studies:
Other Diabetes Insipidus, Nephrogenic Clinical Trials
Other Clinical Trials
Other Clinical Trials
Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus
|
|
|
|
|
|
|
|
